Karvea – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Karvea, as authorised in the European Union and published in the Union Register of medicinal products.
Before anything else
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. ▪ Keep this leaflet. You may need to read it again. ▪ If you have any further questions, ask your doctor or pharma cist. ▪ This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. ▪ If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
ℹ️ 1. What Karvea is and what it is used for
Karvea belongs to a group of medicines known as angiotensin -II receptor antagonists. Angiotensin -II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten.
This results in an increase in blood pressure. Karvea prevents the binding of angiotensin -II to these receptors, causing the blood vessels to relax and the blood pressure to lower. Karvea slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Karvea is used in adult patients ▪ to treat high blood pressure ( essential hypertension ) ▪ to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function.
⚠️ 2. What you need to know before you take Karvea
Do not take Karvea
▪ if you are allergic to irbesartan or any other ingredients of this medicine (listed in section 6) ▪ if you are more than 3 months pregnant . (It is also better to avoid Karvea in early pregnancy – see pregnancy section) ▪ if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren .
Warnings and precautions
Talk to your doctor before taking Karvea and if any of the following apply to you: ▪ if you get excessive vomiting or diarrhoea ▪ if you suffer from kidney problems ▪ if you suffer from heart problems ▪ if you receive Karvea for diabetic kidney disease . In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function ▪ if you develop low blood sugar levels (symptoms may include sweating, weakness, hunger, dizziness, trembling, headache, flushing or paleness, numbness, having a fast, pounding heartbeat), particularly if you are being treated for diabetes. ▪ if you are going to have an operation (surgery) or be given anaesthetics ▪ if you are taking any of the following medicines used to treat high blood pressure:
136 o an ACE -inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes -related kidney problems. o aliskiren Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals .
Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Karvea . Your doctor will decide on further treatment. Do not stop taking Karvea on your own.
See also information under the heading “Do not take Karvea”.
You must tell your doctor if you think you are ( or might become ) pregnant. Karvea is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Children and adolescents
This medicinal product should not be used in children and adolescents because the safety and efficacy have not yet been fully established.
Other medicines and Karvea
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Your doctor may need to change your dose and/or to take other precautions :
If you are taking an ACE -inhibitor or aliskiren (see also information under the headings “Do not take Karvea” and “Warnings and precautions” ).
You may need to have blood checks if you take: ▪ potassium supplements ▪ salt substitutes containing potassium ▪ potassium -sparing medicines (such as certain diuretics) ▪ medicines containing lithium ▪ repaglinide (medication used for lowering blood sugar levels) If you take certain painkillers, called non -steroidal anti -inflammatory drugs, the effect of irbesartan may be reduced.
Karvea with food and drink Karvea can be taken with or without food.
Pregnancy and breast -feeding
Pregnancy
You must tell your doctor if you think you are ( or might become ) pregnant. Your doctor will normally advise you to stop taking Karvea before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Karvea. Karvea is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Breast -feeding Tell your doctor if you are breast -feeding or about to start breast -feeding. Karvea is not recommended for mothers who are breast -feeding, and your doctor may choose another treatment for you if you wish to breast -feed, especially if your baby is newborn, or was born prematurely.
Driving and using machines
Karvea is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.
Karvea contains lactose . If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicin al product.
Karvea contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium -free’.
💊 3. How to take Karvea
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Method of administration Karvea is for oral use . Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water).
You can take Karvea with or without food. Try to take your daily dose at about the same time each day. It is important that you continue to take Karvea until your doctor tells you otherwise. ▪ Patients with high blood pressure The usual dose is 150 mg once -a-day. The dose may later be increased to 300 mg once daily depending on blood pressure response. ▪ Patients with high blood pressure and type 2 diabetes with kidney disease In patients with high blood pressure and type 2 diabetes, 300 mg once daily is the preferred maintenance dose for the treatment of associated kidney disease.
The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on haemodialysis , or those over the age of 75 years.
The maximal blood pressure lowering effect should be reached 4 -6 weeks after beginning treatment.
Use in children and adolescents Karvea should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.
If you take more Karvea than you should
If you accidentally take too many tablets, contact your doctor immediately.
If you forget to take Karvea
If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
❗ 4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some of these effects may be serious and may require medical attention.
As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan. If you get any of these symptoms or get short of breath, stop taking Karvea and contact your doctor immediately.
The frequency of the side effects listed below is defined using the following convention:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
138 Uncommon: may affect up to 1 in 100 people Side effects reported in clinical studies for patients treated with Karvea were: ▪ Very common (may affect more than 1 in 10 people) : if you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium. ▪ Common (may affect up to 1 10 people) : dizziness, feeling sick/vomiting, fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme). In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported. ▪ Uncommon (may affect up to 1 in 100 people) : heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain. ▪ Rare (may affect up to 1 in 1,000 people ): intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting and diarrhoea .
Some undesirable effects have been reported since marketing of Karvea. Undesirable effects where the frequency is not known are: feeling of spinning, headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, decreased number of red blood cells (anaemia – symptoms may include tiredness, headaches, being short of breath when exercising, dizziness and looking pale), reduced number of platelets, abnormal liver function, increased blood potassium levels, impaired kidney function, inflammation of small blood vessels mainly affecting the skin (a condition known as leukocytoclastic vasculitis) , severe allergic reactions (anaphylactic shock) and low blood sugar levels .
Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.
🌡️ 5. How to store Karvea
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
📦 6. Contents of the pack and other information
What Karvea contains
▪ The active substance is irbesartan. Each tablet of Karvea 300 mg contains 300 mg irbesartan. ▪ The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, carnauba wax. Please see section 2 “Karvea contains lactose”.
139 What Karvea looks like and contents of the pack Karvea 300 mg film -coated tablets are white to off -white, biconvex, and oval -shaped with a heart debossed on one side and the number 2873 engraved on the other side.
Karvea 300 mg film -coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets. Unidose blister packs of 56 x 1 film-coated tablet for delivery in hospitals are also available.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Sanofi Winthrop Industrie 82 avenue Raspail 94250 Gentilly France
Manufacturer
SANOFI WINTHROP INDUSTRIE 1, rue de la Vierge Ambarès & Lagrave F-33565 Carbon Blanc Cedex – France SANOFI WINTHROP INDUSTRIE 30-36 Avenue Gustave Eiffel, BP 7166 F-37071 Tours Cedex 2 – France SANOFI -AVENTIS, S.A.
Ctra. C -35 (La Batlloria -Hostalric), km. 63.09 17404 Riells i Viabrea (Girona) – Spain For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
België/Belgique/Belgien Sanofi Belgium Tél/Tel: +32 (0)2 710 54 00 Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 България Swixx Biopharma EOOD Тел.: +359 (0)2 4942 480 Luxembourg/Luxemburg Sanofi Belgium Tél/Tel: +32 (0)2 710 54 00 ( Belgique/Belgien) Česká republika Sanofi s.r.o.
Tel: +420 233 086 111 Magyarország SANOFI -AVENTIS Zrt.
Tel.: +36 1 505 0050 Danmark Sanofi A/S Tlf: +45 45 16 70 00 Malta Sanofi S. r.l.
Tel: +39 02 39394275 Deutschland Sanofi -Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel. aus dem Ausland: +49 69 305 21 131 Nederland Sanofi B.V.
Tel: +31 20 245 4000 140 Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 Norge sanofi -aventis Norge AS Tlf: +47 67 10 71 00 Ελλάδα Sanofi -Aventis Μονοπρόσωπη ΑΕΒΕ Τηλ: +30 210 900 16 00 Österreich sanofi -aventis GmbH Tel: +43 1 80 185 – 0 España sanofi -aventis, S.A.
Tel: +34 93 485 94 00 Polska Sanofi Sp. z o.o.
Tel.: +48 22 280 00 00 France Sanofi Winthrop Industrie Tél: 0 800 222 555 Appel depuis l’étranger: +33 1 57 63 23 23 Portugal Sanofi – Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 Hrvatska Swixx Biopharma d.o.o.
Tel: +385 1 2078 500 România Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 Ireland sanofi -aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 Slovenija Swixx Biopharma d.o.o .
Tel: +386 1 235 51 00 Ísland Vistor ehf.
Sími: +354 535 7000 Slovenská republika Swixx Biopharma s.r.o.
Tel: +421 2 208 33 600 Italia Sanofi S. r.l.
Tel: 800 536389 Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 Κύπρος C.A. Papaellinas Ltd.
Τηλ: +357 22 741741 Sverige Sanofi AB Tel: +46 (0)8 634 50 00 Latvija Swixx Biopharma SIA Tel: +371 6 616 47 50
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/
📄 Package Leaflet – official source
This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Karvea (PDF, ec.europa.eu).
You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/97/049).
⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.